BCG vaccine trial update, with Professor Andreas Diacon

Loading player...
Stellenbosch University Professor Andreas Diacon is the force behind a 500-person clinical trial aimed at determining whether the BCG vaccines many South Africans got as children to protect against TB are indeed a shield against Covid-19. The trial involves revaccination of BCG that’s been universally applied in South Africa since 1973. Numerous reports have pointed out a correlation between infection rates for countries where BCG is universally administered as being far lower than in those countries like the USA, Italy and Belgium where it was never used. Learn more about your ad choices. Visit megaphone.fm/adchoices
13 Jul 2020 6AM English South Africa Investing · Business News

Other recent episodes

The BizNews Edge: African Bank's Billion-Rand Acquisition Trap

African Bank swung to a loss of nearly a billion rand after a four-year spree of buying and bolting together three banks to build a full-service lender, and the bad debt charge is still climbing. The contrast is brutal: a focused platinum-and-chrome miner, Tharisa, is printing cash with profit up…
25 Jun 7AM 9 min

The BizNews Edge: Nedbank, Grindrod and the coal stock no one was watching

Nedbank confirmed its guidance this morning, and its East Africa deal is weeks from closing - a transformation most investors are still underpricing. Grindrod's Port of Maputo posted extraordinary volumes, but the share may already be priced for perfection. A small coal miner no one follows just disclosed an 1,800%…
24 Jun 8AM 26 min